UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Medulloblastoma

Journal of child neurology, 2016-10, Vol.31 (12), p.1341-1353

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

PloS one, 2017-06, Vol.12 (6), p.e0178593-e0178593

2017

Link zum Volltext

Verfügbarkeit prüfen

Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival

Pediatric blood & cancer, 2015-04, Vol.62 (4), p.611-615

2015

Link zum Volltext

Verfügbarkeit prüfen

The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review

Cancers, 2023-12, Vol.15 (24), p.5746

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Frontiers in immunology, 2024-06, Vol.15, p.1405452

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

Journal of neuro-oncology, 2010-12, Vol.100 (3), p.443-447

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

Pediatric blood & cancer, 2017-07, Vol.64 (7), p.n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Blood cancer journal (New York), 2022-02, Vol.12 (2), p.32-32, Article 32

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy

Journal of neuro-oncology, 2018-01, Vol.136 (1), p.95-104

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET)

Current treatment options in neurology, 2013-10, Vol.15 (5), p.593-606

2013

Link zum Volltext

Verfügbarkeit prüfen

Patterns of relapse for children with localized intracranial ependymoma

Journal of neuro-oncology, 2018-06, Vol.138 (2), p.435-445

2018

Link zum Volltext

Verfügbarkeit prüfen

(P024) Reduced-Volume Radiotherapy for Patients With Localized Intracranial Nongerminoma Germ Cell Tumors

International journal of radiation oncology, biology, physics, 2017-06, Vol.98 (2), p.E21-E21

2017

Link zum Volltext

Verfügbarkeit prüfen

Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors

Journal of neuro-oncology, 2017-09, Vol.134 (2), p.349-356

2017

Link zum Volltext

Verfügbarkeit prüfen

Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival

Pediatric blood & cancer, 2015-04, Vol.62 (4), p.611-615

2015

Link zum Volltext

Verfügbarkeit prüfen

The molecular basis of pyruvate carboxylase deficiency: Mosaicism correlates with prolonged survival

Molecular genetics and metabolism, 2008-09, Vol.95 (1), p.31-38

2008

Link zum Volltext

Verfügbarkeit prüfen

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer

Current neurology and neuroscience reports, 2008-03, Vol.8 (2), p.114-122

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Medulloblastoma

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival

The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy

Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET)

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Patterns of relapse for children with localized intracranial ependymoma

(P024) Reduced-Volume Radiotherapy for Patients With Localized Intracranial Nongerminoma Germ Cell Tumors

MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy

Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors

Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival

The molecular basis of pyruvate carboxylase deficiency: Mosaicism correlates with prolonged survival

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Suchergebnisse filtern